Eimskipafelag Islands hf.
11.3.2021 16:40:41 CET | Globenewswire | Press release
Enclosed is the final agenda and proposals from the Board of Directors for the 2021 Annual General Meeting, along with the report of the Company's Nomination Committee.
Eimskipafélag Íslands hf.'s Annual General Meeting will be held on Thursday 25 March 2021 at 16:00 (GMT) at Gullteigur conference room, Grand Hotel, Sigtúni 28, 104 Reykjavík.
Shareholder’s attention is brought to the fact that the meeting will be arranged in accordance with the COVID-19 measures from the Government of Iceland and Icelandic Act respecting Public Limited Companies, applicable at the meeting date. Should the Company need to alter the meetings arrangement a press release will be published at Nasdaq Iceland at least 48 hours before the meeting. Further information on the meeting arrangement will be published next week.
For further information, please visit the Company's website www.eimskip.com/investors
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sveriges Riksbank2.10.2026 16:20:00 CEST | Press release
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS
Virtune AB (Publ)2.10.2026 15:25:12 CEST | Press release
Virtune AB (Publ) (“Virtune”) has completed the monthly rebalancing for October 2026 of its Virtune Crypto Top 10 Index ETP - the first crypto index ETP in the Nordics
Evaxion2.10.2026 15:00:00 CEST | Press release
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Teva Pharmaceutical Industries Ltd2.10.2026 14:00:00 CEST | Press release
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
Teva Pharmaceutical Industries Ltd2.10.2026 14:00:00 CEST | Press release
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
